Skip to main content

Philips extends AI portfolio with launch of IntelliSpace AI Workflow Suite to seamlessly integrate applications across imaging workflows

Written by Customer Service on . Posted in Public Companies.


December 1, 2019
Comprehensive platform launching with an ecosystem of applications from partners including Aidoc, MaxQ AI, Quibim, Riverain Technologies and Zebra MedicalChicago, U.S. and Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of IntelliSpace AI Workflow Suite [1] to enable healthcare providers to seamlessly integrate AI applications into the imaging workflow. Part of Philips’ new enterprise imaging informatics solution, the comprehensive AI workflow platform provides a full suite of applications for integration and centralized workflow management of AI algorithms, delivering structured results wherever they’re needed across the healthcare enterprise. Partners at launch include Aidoc, MaxQ AI, Quibim [2], Riverain Technologies and Zebra Medical.IntelliSpace AI Workflow Suite is being unveiled at the 2019 Radiological Society of North America Annual Meeting (RSNA). Leiden University Medical Center (LUMC) in the Netherlands recently signed an agreement to be the first healthcare provider to install the platform.A comprehensive solution that seamlessly integrates with existing workflows
Integrating into existing department and hospital infrastructure, the suite automatically orchestrates the routing of clinical data to the appropriate AI application within the healthcare provider’s ecosystem to allow data analysis without user interaction, and displays the results. The suite is designed to support Philips’ commitment to providing open, comprehensive solutions to healthcare providers’ AI imaging needs. Natively integrating with Philips’ diagnostic imaging and informatics solutions, IntelliSpace AI Workflow Suite can also be used alongside imaging solutions from other vendors. In addition, the suite is designed to support the training of site-specific AI applications based on local data.Philips recognized for AI leadership
Philips was recently recognized by Frost & Sullivan as Company of the Year for Artificial Intelligence for Enhanced Radiology Interpretation, thanks to the company’s approach to imaging AI as a disruptive imaging informatics strategy. Recognized for AI combining with deep knowledge of the clinical and operational context in which it is used, Philips is embedding AI within imaging workflows across multiple touchpoints to better personalize the patient care pathway.“AI is already supporting clinical decision-making and increasing efficiency in imaging departments,” said Calum Cunningham, General Manager Enterprise Diagnostic Informatics at Philips. “Philips is among the top three companies in the world in terms of AI-related patent applications in healthcare. With the IntelliSpace AI Workflow Suite we’re enabling healthcare providers to take a comprehensive, future-proof approach to integrating AI applications that maximizes their benefits while ensuring seamless integration into existing workflows.”AI-enabled imaging applications and AI algorithms are playing an important role in achieving the ‘quadruple aim’ in healthcare: better health outcomes, lower cost of care, and an improved experience for patients and staff. As the number of applications and vendors increases, healthcare providers risk being overwhelmed by technical integration challenges as well as administrative overhead. By seamlessly integrating AI applications from Philips’ partners, the Philips IntelliSpace AI Workflow Suite enables healthcare providers to capitalize on the latest AI applications, increase diagnostic confidence and efficiency without adding complexity.Philips IntelliSpace AI Workflow Suite is launching with applications including:Aidoc: applications including intracranial hemorrhage, C-spine fractures, and pulmonary embolismMaxQ AI: applications including the company’s ACCIPIO® intracranial hemorrhage and stroke platformQuibim: applications including brain lesions detection, chest X-ray classifier, emphysema, liver fat and iron concentration, and brain atrophy analysis [2]Riverain Technologies: applications including the company’s ClearRead bone suppression and ClearRead CTZebra Medical: applications including intracranial hemorrhage and pneumothoraxPart of Philips’ next-generation enterprise imaging informatics solution
IntelliSpace AI Workflow Suite is part of Philips’ next-generation enterprise imaging informatics solution. The introduction follows several years of strategic investments in R&D, AI and complementary acquisitions, resulting in a suite of integrated products that deliver a comprehensive platform designed to connect clinical capabilities and optimize workflows around every step in the patient’s journey.Philips is demonstrating its imaging solutions at the 2019 Radiological Society of North America (RSNA) Annual Meeting in booth #6730. In addition to its main presence (booth #6730), Philips will also have a strong presence in the AI Showcase hall (North Hall Level 1, booth #10109). For more information about Philips’ presence at RSNA, including its program of live talks on a range of topics including AI in radiology, visit www.philips.com/RSNA, and follow @PhilipsLiveFrom for #RSNA19 live updates.[1] IntelliSpace AI Workflow Suite is not intended for diagnosis or treatment selection. Work in progress, not available for sale.
[2] Applications from Quibim are not 510(k) cleared and not available for sale in the USA.For further information, please contact:Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
Email: mark.groves@philips.com
Twitter: @mark_grovesAbout Royal Philips

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.